Actively Recruiting
HIV Prevention and Care Interventions for Youth in Uganda
Led by MU-JHU CARE · Updated on 2025-07-29
600
Participants Needed
1
Research Sites
212 weeks
Total Duration
On this page
Sponsors
M
MU-JHU CARE
Lead Sponsor
M
Makerere University Joint AIDS Program
Collaborating Sponsor
AI-Summary
What this Trial Is About
Several studies show that Adolescents and Young Adults (AYA) have poor outcomes along the entire Human Immunodeficiency Virus (HIV) prevention and care cascades compared to adults. The investigators propose to evaluate novel evidence-based HIV prevention and care interventions (including Cabotegravir LongActing (CABLA) to determine implementation outcomes among AYA who are at particularly high risk for HIV acquisition and poor viral suppression in five geographically distinct research performance sites in Uganda. The results will provide important evidence to inform Uganda and other regional countries' policy on integrated HIV prevention, care and treatment for AYA at high risk for HIV and Sexually Transmitted Infections (STIs) in order to reach the UNAIDS 95-95-95 targets and HIV epidemic control.
CONDITIONS
Official Title
HIV Prevention and Care Interventions for Youth in Uganda
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adolescents and young adults aged 15 to 24 years
- Classified as high risk for HIV acquisition using the study screening tool
- Documented HIV negative status by national testing algorithm and willing to use PrEP
- Willing to provide written informed consent
- No plans to relocate permanently within the next 6 months
- No suspicion of acute HIV infection, Hepatitis B surface antigen negative and accepting Hepatitis B vaccination
- No medical or social conditions that would interfere with study participation
- For HIV positive participants: willing to receive antiretroviral therapy at participating health facilities
- HIV positive participants must have high-risk features for viral load non-suppression such as missed visits, disengagement, new to care, or non-suppressed viral load on last test
- Willing to provide written informed consent
- No plans to relocate permanently within the next 6 months
- No medical or social conditions that would interfere with study participation
You will not qualify if you...
- One or more reactive HIV test results at screening or enrollment for HIV negative group
- Cognitive impairment preventing understanding of study procedures or informed consent
- Plans to move out of the study area during the study period
- Enrollment in another intervention study
- Already on oral PrEP or unwilling/unable to commit to using CAB-LA
- Ineligible for CAB-LA as per Uganda national PrEP guidelines
- Hepatotoxicity or Hepatitis B infection
- Potential HIV exposure in past 72 hours
- Signs or symptoms of acute HIV infection
- Current or chronic liver disease, seizure disorder, cardiovascular disease, coagulopathy, or inflammatory skin conditions
- Hypersensitivity to CAB-LA or integrase inhibitors
- For HIV positive group: unable to give written informed consent or not receiving care at selected facilities
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
MU-JHU Care Ltd
Kampala, Uganda
Actively Recruiting
Research Team
P
Philippa Musoke, MBChB, PhD
CONTACT
J
Judith Mbanza, M.A. MSc.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here